Guidance for Industry: Policy Regarding N-acetyl-L-cysteine

August 1, 2022

Close-up of a supplement bottle with N-acetyl-L-cysteine as an ingredient.

Guidance Document

August 2022

The purpose of this guidance is to advise dietary supplement manufacturers, distributors, and other stakeholders of our intent to exercise enforcement discretion with respect to the sale and distribution of certain products that contain N-acetyl-L-cysteine (NAC) and are labeled as dietary supplements. As described below, the enforcement discretion policy applies to products that would be lawfully marketed dietary supplements if NAC were not excluded from the definition of “dietary supplement” and that are not otherwise in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

Download the Final Guidance Document

Read the Federal Register Notice

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs


Two gloved hands drawing blood from a finger.

August 16, 2022

Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices

GUIDANCE DOCUMENT - Guidance for Industry and FDA Staff AUGUST 2022 In 2003, FDA issued an updated guidance on the "Replacement Reagent and Instrument Family Policy" for in vitro diagnostic (IVD)...

August 8, 2016

FDA Establishes Policy for the Regulation of General Wellness Products

On Friday, July 29th, the FDA issued a final guidance document entitled “General Wellness: Policy for Low Risk Devices,” which clarifies FDA’s Center for Devices and Radiological Health’s (CDRH’s)...

February 29, 2016

FDA Compliance Policy: Requirements for Transactions with First Responders Under the FD&C Act

As FDA’s Track-and-Trace Requirements go Into Effect, the Agency Issues a New Guidance for Trading Partners Engaged in Transactions with First Responders On February 29, 2016, the FDA published a...